| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data presentation example | Phase 1/2 | — | Subscribe to access the data. | Cell Therapies | Rare Diseases | ||
Phase 1/2 data presentation example | Phase 1/2 | — | Subscribe to access the data. | Cell Therapies | Rare Diseases | ||
Phase 1/2 data presentation example | Phase 1/2 | — | Subscribe to access the data. | Cell Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
Nkarta, Inc.
$2.81
-0.1 (-3.44%)
C 40Pipeline Score Undervalued Biotech · Clinical
Market Cap
201.27 M
EPS
-1.64
P/E Ratio
-
Value Trade
1.30 M
-3.77 %
Week
17.57 %
1 Month
-1.75 %
3 Month
24.34 %
6 Month
-89.09 %
5 Year
-94.47 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
559.28 K
52 Week Range
1.70 - 3.72
% held by Insiders
23.61 %
% held by Institutions
64.22 %
Enterprise Value
18.50 M
Total Shares
71.62 M
Short %
8.18 %
Float Shares
42.05 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nkarta, Inc.
287Total events
7Upcoming
35Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 2
TBD
T2R&D Day
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
●Enrollment UpdateNKX101Trial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-09-30 | NKXO19 | Phase 1 data readout | Phase 1 | — | – | – | – |
2024-09-30 | NKXO19 | Phase 1 data readout | Phase 1 | — | – | – | – |
2024-09-30 | NKXO19 | Phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
C40
Pipeline Score $258M
Pipeline ValueUndervalued
Valuation Signal2
Drugs Scored4.1x
rNPV / MCap Top 62%
Micro Cap (rank 357 of 938)
Percentile RankNkarta, Inc. carries a moderate pipeline score (40/100), with $2.9B risk-adjusted pipeline value, led by NKX101- CAR NK cell therapy in Relapsed/Refractory AML (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NKX101- CAR NK cell therapy Monoclonal antibody | Relapsed/Refractory AML | Phase 1 | NCT04623944 | 9% | $2.5B | ACTIVE NOT_RECRUITING | 61 | SLOW | D (24) | Jul 1, 2039 | MODERATE_RISK | Dec 27, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NKX101 | relapsed or refractory acute myeloid leukemia (r/r AML) | Phase 1 | 2023-12-10 | three out of four patients who initially achieved complete responses maintained those responses four months after treatment; four of six achieved CR/CRi Read More | Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition Read More | |
NKX101 | relapsed or refractory acute myeloid leukemia (r/r AML) | Phase 1 | 2023-12-10 | three out of four patients who initially achieved complete responses maintained those responses four months after treatment; four of six achieved CR/CRi Read More | Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition Read More | |
NKX101 | relapsed or refractory acute myeloid leukemia (r/r AML) | Phase 1 | 2023-12-10 | three out of four patients who initially achieved complete responses maintained those responses four months after treatment; four of six achieved CR/CRi Read More | Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NKTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NKTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NKTX▼ -3.4%today
Nkarta to Participate in September Investor Conferences
Nkarta, Inc. announced its participation in two upcoming investor conferences in September 2026. The events include the H.C. Wainwright 28th Annual Global Investment Conference and the Stifel 2026 Virtual Immunology and Inflammation Forum. Nkarta focuses on developing engineered NK cell therapies for autoimmune diseases, providing accessible treatment options.
Read more →NKTX▲ +10.6%on this newsshared move
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
Nkarta, Inc. announced its selection for three presentations at ACR Convergence 2026, showcasing initial clinical data for NKX019, an investigational CAR-NK cell therapy. The presentations will highlight the therapy's safety and clinical activity in idiopathic inflammatory myopathy and systemic sclerosis. CEO Paul J. Hastings emphasized the potential of NKX019 to improve patient access to treatment.
Read more →NKTX▼ -5.3%on this news
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
Nkarta has reported its financial results for the second quarter of 2026, highlighting ongoing enrollment in its Ntrust-1 and Ntrust-2 clinical trials at a high cell dose level. The company anticipates presenting initial clinical data from these trials at a medical conference in 2026. As of June 30, 2026, Nkarta's cash balance stands at $243.2 million.
Read more →NKTXNkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Nkarta, Inc. will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30th. President Nadir Mahmood will discuss the company's investigational CAR-NK cell therapy targeting B cell-mediated autoimmune diseases. The event will be available via webcast and archived for 90 days.
Read more →NKTXNkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Nkarta, Inc. reported its Q1 2026 financial results, highlighting ongoing enrollment in clinical trials Ntrust-1 and Ntrust-2 for NKX019, an engineered NK cell therapy for autoimmune diseases. A regulatory agreement allows outpatient dosing to improve patient access. The company has a cash balance of $266.7 million, expected to sustain operations until 2029, with initial clinical data projected for release in 2026.
Read more →NKTX▲ +15.7%on this news· ran to +43% by day 1
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
Nkarta, Inc. has reached an agreement with the FDA to amend protocols for its Ntrust-1 and Ntrust-2 clinical trials, allowing outpatient dosing of NKX019. This change is expected to reduce patient monitoring time and expand access to treatment through community rheumatology centers. The trials will now include patients with rheumatoid arthritis after final protocol submission.
Read more →NKTXNkarta to Participate in Needham Virtual Healthcare Conference
Nkarta, Inc. will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. CEO Paul Hastings will join a panel discussion on cell therapy in autoimmune diseases, while President Nadir Mahmood will provide updates on their investigational CAR-NK cell therapy. The event will be accessible via webcast.
Read more →NKTXNkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
Nkarta, Inc. reported its financial results for Q4 and the full year 2025, highlighting strategic advancements in its CAR-NK cell therapy platform for autoimmune diseases. The company is currently dosing patients with NKX019 and plans to present clinical updates later this year. With a cash runway extending into 2029, Nkarta is focused on disciplined execution of its clinical programs.
Read more →NKTXNkarta to Participate in March Investor Conferences
Nkarta, Inc. announced its participation in two upcoming investor conferences in March 2026. The events include the TD Cowen 46th Annual Health Care Conference and the Leerink Global Healthcare Conference, where Nkarta will host fireside chats. Both events will be available via webcast, enhancing accessibility for investors.
Read more →NKTXNkarta to Participate in Evercore Healthcare Conference 2025
Nkarta, Inc. will participate in the Evercore 8th Annual Healthcare Conference on December 4, 2025. The event will feature a fireside chat at 10:50 a.m. ET and will be available via a webcast. Nkarta focuses on developing engineered NK cell therapies aimed at treating autoimmune diseases, enhancing outpatient treatment accessibility.
Read more →NKTXNkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
Nkarta, Inc. reported its third quarter 2025 financial results, highlighting significant progress in the NKX019 clinical program for autoimmune diseases. The company has streamlined patient enrollment in its Ntrust trials and modified its treatment regimen to achieve complete B-cell depletion. With FDA clearance for study design changes, Nkarta is set to advance its clinical program while maintaining a strong financial outlook.
Read more →NKTXNkarta to Participate in November Investor Conferences
Nkarta, Inc. has announced its participation in two upcoming investor conferences in November 2025. The events include a fireside chat at the Stifel 2025 Healthcare Conference on November 12 and another at TD Cowen’s Immunology & Inflammation Summit on November 13. A webcast of these events will be available on their website.
Read more →NKTXNkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
Nkarta, Inc. will present clinical data on its investigational therapy NKX019 at the ACR Convergence 2025 meeting. The data indicates NKX019 effectively depletes pathogenic B cells, showing potential for treating autoimmune diseases. The presentation will take place on October 26, with additional information available at their booth.
Read more →NKTXNkarta to Participate in a September Investor Conference
Nkarta, Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 2025. The company will present a fireside chat, accessible via a live webcast and archived on their website for 90 days. Nkarta focuses on developing engineered natural killer (NK) cell therapies aimed at treating autoimmune diseases, utilizing advanced cell engineering technologies. This event highlights the company's progress and commitment to innovation in biopharmaceuticals.
Read more →NKTXNkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights • Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025 • Cash balance of $334.0 million
Nkarta, Inc. reported its second quarter 2025 financial results, noting a cash balance of $334 million that is anticipated to fund operations through 2029. The company continues to advance its clinical trials for NKX019, with initial updates expected in the latter half of 2025 for various autoimmune conditions. Despite a net loss of $23 million, the appointment of Dr. Shawn Rose as CMO is expected to bolster Nkarta’s clinical efforts in autoimmune therapies. Ongoing trials include Ntrust-1 and Ntrust-2, focusing on safety and efficacy in autoimmune disease treatment.
Read more →NKTX▲ +7.2%on this news
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
Nkarta, Inc. announced its participation in the H.C. Wainwright 'HCW@Home' Series, scheduled for July 30, 2025. The event will feature a fireside chat at 11:00 a.m. ET, and a webcast will be available for those unable to attend live. Nkarta is focused on developing engineered NK cell therapies for autoimmune diseases.
Read more →NKTXNkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
Nkarta, Inc. has appointed Dr. Shawn Rose as Chief Medical Officer and Head of R&D, effective June 23, 2025. He replaces Dr. David Shook, who is leaving to pursue opportunities in oncology. Dr. Rose brings extensive experience in immunology and has a history of advancing clinical programs. His leadership is expected to enhance Nkarta's efforts in developing NK cell therapies for autoimmune diseases.
Read more →NKTXNkarta Reports First Quarter 2025 Financial Results and Corporate Highlights • Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemi
Nkarta, Inc. has reported its financial results for the first quarter of 2025, highlighting the opening of enrollment for several investigator-sponsored trials of NKX019. The company plans to utilize a modified lymphodepletion regimen to enhance the efficacy of its trials. Despite facing a net loss of $32 million, Nkarta maintains a robust cash balance of $351.9 million, which it expects will support operations through 2029. The trials aim to provide initial clinical data in the second half of 2025, potentially addressing unmet needs in various autoimmune diseases.
Read more →NKTXNkarta to Participate in an April Investor Conference
Nkarta, Inc. has announced its participation in an upcoming investor conference, which will be accessible via a webcast. The company focuses on developing engineered NK cell therapies for autoimmune diseases, utilizing advanced technologies like CRISPR. A replay of the event will be available on their website for 90 days.
Read more →NKTXNkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights • Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019
Nkarta, Inc. announced its financial results for the fourth quarter and full year 2024, highlighting a restructured development program for NKX019 in autoimmune diseases. The company projects that its cash reserves will sustain operations through 2029 despite a workforce reduction of 34% to extend its cash runway. Initial clinical data from two ongoing trials is expected in late 2025, showcasing Nkarta's commitment to advancing CAR NK cell therapies despite facing challenges, including significant financial losses.
Read more →NKTXNkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta, Inc. announced the IND clearance and enrollment opening for the Ntrust-2 trial, which will evaluate NKX019 in myasthenia gravis patients. This investigator-sponsored trial will assess NKX019's safety and efficacy across three cohorts focusing on systemic sclerosis, myositis, and ANCA-associated vasculitis. NKX019 is an innovative CAR NK-cell therapy designed for targeted treatment in autoimmune diseases. The dual-center, open-label study highlights Nkarta's commitment to enhancing treatment paradigms in autoimmune conditions.
Read more →NKTXNkarta to Participate in an Upcoming Investor Conference
Nkarta, Inc. (Nasdaq: NKTX), a company focused on developing engineered natural killer (NK) cell therapies, will participate in the 7th Annual Evercore HealthCONx Conference. The event will feature a fireside chat at 2:10 p.m. ET, with a simultaneous webcast available for viewers. Nkarta's advancements include allogeneic, off-the-shelf therapies that utilize a proprietary cell engineering platform and CRISPR technology. This participation reflects the company's ongoing commitment to expanding its therapeutic pipeline.
Read more →NKTXNkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights • First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studies
Nkarta, Inc. reported its Q3 2024 financial results and highlighted significant milestones in the clinical development of NKX019. The first patient has been dosed in both the Ntrust-1 trial and an investigator-sponsored trial for systemic lupus erythematosus, with ongoing enrollment in both studies. The company plans to prioritize the advancement of NKX019 for autoimmune diseases and aims to initiate enrollment in the Ntrust-2 trial by the end of 2024. Additionally, Nkarta has decided to discontinue further development of NKX019 in non-Hodgkin lymphoma based on recent clinical data.
Read more →NKTXNkarta to Participate in Upcoming Investor Conference
Nkarta, Inc. (Nasdaq: NKTX) has announced its forthcoming participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company will host a fireside chat at 12:30 p.m. ET, which will also be streamed via webcast for interested investors. Nkarta specializes in developing engineered natural killer (NK) cell therapies, showcasing its commitment to expanding access to innovative biopharmaceutical treatments.
Read more →NKTXNkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights • Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of
Nkarta, Inc. reported its second quarter 2024 financial results, highlighting a strong cash position of $426.7 million, which is expected to fund operations into late 2027. The company anticipates initiating enrollment in its Ntrust-2 clinical trial for NKX019, targeting autoimmune diseases such as systemic sclerosis and myositis, by year-end 2024. Additionally, promising follow-up data from previous trials in non-Hodgkin lymphoma indicates potential for this therapy. However, Nkarta faces ongoing challenges due to a reported net loss of $25 million in the fiscal quarter.
Read more →NKTXNkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
Nkarta, Inc. has announced the commencement of an investigator-sponsored clinical trial for NKX019, an allogeneic CAR NK-cell therapy, aimed at treating systemic lupus erythematosus (SLE). The trial, led by researchers at Columbia University, will enroll up to six patients and will investigate the safety and efficacy of NKX019. This initiative follows a recent Phase 1 trial for NKX019 in lupus nephritis, expanding its clinical evaluation in the lupus population. The therapy aims to reduce the need for toxic medications while promoting healthier outcomes for patients with autoimmune diseases.
Read more →NKTX▲ +14%on this news
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
Nkarta, Inc. has announced significant changes to its leadership team, appointing Nadir Mahmood, Ph.D., as President and promoting David R. Shook, M.D., to Chief Medical Officer. The leadership restructuring aims to enhance Nkarta's capacity to advance cell therapy, particularly with their NKX019 programs targeting autoimmune diseases. Mahmood's background and previous role at Nkarta signal a strong strategic emphasis on innovation. The company is set to initiate further clinical trials for NKX019, reinforcing its commitment to developing novel therapies for patients in need.
Read more →NKTXNkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications Patient screening underway in Ntrust-1, the first U.S.-ba
Nkarta, Inc. has commenced its Ntrust-1 clinical trial for NKX019, targeting lupus nephritis, with the first patient currently in screening. The company has also received FDA clearance for a new trial, Ntrust-2, which will assess NKX019 in additional autoimmune conditions such as systemic sclerosis and myositis. This expansion highlights Nkarta's commitment to improving accessibility and safety in cell therapy for patients with autoimmune diseases, aiming for better treatment outcomes by targeting harmful B cells.
Read more →NKTXNkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors Senior R&D leader brings extensive expertise in immunology, clinical development and translational science
Nkarta, Inc. has announced the addition of Dr. George Vratsanos to its board of directors, bringing extensive experience in immunology and clinical development. Previously serving in key roles at Jnana Therapeutics and Janssen Pharmaceuticals, Dr. Vratsanos expressed excitement about supporting Nkarta's innovative work in natural killer cell therapy. The company is focusing on developing NKX019, an off-the-shelf therapy aimed at treating lupus nephritis by utilizing engineered natural killer cells. This strategic appointment is expected to strengthen Nkarta's capabilities in advancing their cell therapy programs.
Read more →NKTXNkarta Reports First Quarter 2024 Financial Results and Corporate Highlights • Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024 •
Nkarta reported its financial results for Q1 2024, highlighting a cash balance of $450 million and the anticipated dosing of the first patient with NKX019 for lupus nephritis in the first half of 2024. The company is developing NKX019, an allogeneic NK cell therapy, to treat autoimmune diseases, and expects to make progress in clinical trials targeting additional conditions. Despite a net loss of $29.5 million during the quarter, Nkarta remains optimistic due to its strong financial position backed by a recent funding raise.
Read more →NKTXNkarta to Participate in Upcoming Investor Conferences
Nkarta, Inc. announced its participation in two upcoming investor conferences, the Needham Virtual Healthcare Conference and the Canaccord Genuity Horizons in Oncology Virtual Conference. During these events, Nkarta will host a fireside chat and a panel discussion, respectively. The company is focused on transforming cancer treatment through its engineered natural killer (NK) cell therapies. Webcasts of the conferences will be available on Nkarta's website, promoting transparency and access to information for investors.
Read more →NKTX▲ +17.6%on this news
Forward-looking statements This presentation contains forward‐looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of the c
The presentation outlines the future prospects of NKTX's cell therapy initiatives, particularly the development of NKX019 aimed at treating autoimmune diseases and cancers. The company highlights the expected updates from their clinical programs in 2024 and the continuation of patient enrollment for various studies. The product candidates are engineered to enhance target cell elimination through allogeneic natural killer cells, which may offer a new modality in treatment strategies within the biopharma landscape.
Read more →NKTX▲ +17.6%on this news
Nkarta Announces Pricing of $240 Million Underwritten Offering
Nkarta, Inc. has announced the pricing of an underwritten offering totaling approximately $240.1 million through the sale of shares and pre-funded warrants. The offering will facilitate the continued research and clinical development of its NKX019 therapy and enhance manufacturing capabilities. It is supported by investments from various well-known investors and is expected to close on or about March 27, 2024, pending customary conditions.
Read more →NKTXNkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights • First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailo
Nkarta Inc. reported its fourth quarter and full year 2023 financial results, highlighting strong financial health with $250.9 million in cash reserves. The company is on track for its first patient dosing of the NKX019 clinical trial in lupus nephritis within the first half of 2024. Optimizing their focus, Nkarta has deprioritized the development of NKX101 due to lower-than-anticipated response rates, directing resources towards NKX019 in autoimmune disease. The potential of NKX019 is emphasized as transformative, with ongoing evaluations for additional indications.
Read more →NKTXNkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
Nkarta presented encouraging follow-up data for its NKX101 therapy at the 2023 ASH Annual Meeting. The Phase 1 clinical trial showed that three out of four patients who initially achieved complete responses maintained those responses four months after treatment. Notably, there were no reports of serious adverse events such as cytokine release syndrome or neurotoxicity. Nkarta plans to continue its evaluation of NKX101 and intends to share further updates on additional patients in the first half of 2024.
Read more →NKTXNkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights • FDA clearance of IND for NKX019 in lupus nephritis expands pipeline into autoimmune disease • NKX019, a first-in-class engineer
Nkarta, Inc. reported its third-quarter financial results for 2023, highlighting key advances in its NK cell therapy pipeline, particularly with the FDA's clearance for NKX019 to treat lupus nephritis. This first-in-class engineered NK cell therapy aims to provide disease-modifying effects for patients with autoimmune diseases. The company is partnered with Lupus Therapeutics to facilitate clinical evaluations through esteemed academic centers. Despite a net loss of $25.6 million in the quarter, Nkarta's financial position remains strong with cash reserves extending its operational runway into 2026.
Read more →NKTXNkarta to Participate at Upcoming Investor Conferences
Nkarta, Inc. has announced its participation in two upcoming investor conferences, the Stifel Healthcare Conference and the Evercore ISI HealthCONx Conference. Both events will feature fireside chats and offer a platform for Nkarta to discuss its engineered natural killer (NK) cell therapies. A webcast of these events will be available on Nkarta's website, providing broad access for interested parties. This engagement highlights Nkarta's advancements in developing innovative biopharmaceutical treatments.
Read more →NKTX▲ +112.2%on this news
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures Call scheduled for Tuesday
Nkarta, Inc. will host a conference call on October 17, 2023, at 8:00 a.m. ET to provide updates on its clinical pipeline and discuss organizational cost measures. The session will focus on resource prioritization meant to support the company's clinical milestones. Nkarta specializes in engineered natural killer cell therapies, leveraging advanced technology to enhance therapeutic efficacy. The call will be available for playback on their website afterward.
Read more →NKTX▲ +112.2%on this news
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
Nkarta, Inc. has received FDA clearance for its IND application to evaluate NKX019, an allogeneic CAR NK cell therapy, for lupus nephritis treatment. This therapy targets CD19+ B cells and seeks to provide a novel treatment opportunity for patients suffering from this severe autoimmune disease. With a robust cash position extending its runway into 2026, Nkarta plans to execute clinical trials while managing operational costs. The company aims for clinical data readouts in 2024 across its pipeline to assess NKX019's efficacy and safety in lupus nephritis.
Read more →NKTX▼ -5.8%on this news
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell
Nkarta, Inc. has received FDA clearance for its IND application to evaluate NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, aimed at treating lupus nephritis. This new program builds on previous academic studies suggesting it could provide durable, drug-free remissions for patients. The company plans to conduct a multi-center clinical trial assessing the safety and efficacy of NKX019 in patients with refractory lupus nephritis. Additionally, Nkarta has implemented cost containment measures to extend its financial resources through 2026, supporting its ongoing clinical programs.
Read more →NKTXNkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights • NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lym
Nkarta reported its second quarter 2023 financial results, highlighting encouraging clinical updates for NKX101, an immunotherapy for acute myeloid leukemia (AML). The therapy demonstrated a 67% complete response rate in severely pre-treated patients. NKX019, another leading therapy, also showed promise, with clinical updates expected in the latter half of 2023. The company has sufficient financial resources, with $302.2 million projected to support operations into 2025.
Read more →NKTXNkarta to Participate at Upcoming Investor Conference
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company, will participate in the Canaccord Genuity 43rd Annual Growth Conference. The event features a fireside chat scheduled for 12:00 p.m. ET. Nkarta is focused on developing engineered natural killer cell therapies, utilizing advanced technologies like CRISPR for improving cancer treatment effectiveness. A webcast of the event will be available on their website, allowing broader access to the discussion.
Read more →NKTXNkarta Appoints Alyssa Levin Chief Financial and Business Officer
Nkarta, Inc. has appointed Alyssa Levin as Chief Financial and Business Officer, effective July 5, 2023. Levin, who previously held senior financial roles at Viacyte and other biotech companies, is expected to drive business transformation at Nkarta. Her expertise comes as the firm aims to accelerate its lead NK cell therapy programs, NKX101 and NKX019. Levin expressed enthusiasm about joining a mission-driven organization with aspirations to advance innovative cancer treatments.
Read more →NKTX▼ -38%on this news· ran to -52% by day 3
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia • Encouraging antileukemic activity seen with NKX101 in patients with AML, including s
Nkarta, Inc. announced positive updates on its CAR-NK cell therapy NKX101 for relapsed or refractory acute myeloid leukemia (AML), revealing that 67% of patients achieved a complete response. The therapy was well tolerated across various dose levels, with no serious adverse events reported. Supported by promising results from a small patient cohort, Nkarta plans to expand the study and provide further clinical updates in the first half of 2024.
Read more →NKTX▼ -38%on this news· ran to -52% by day 3
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program Call scheduled for Tuesday
Nkarta, Inc. announced a conference call scheduled for June 27, 2023, to discuss updated clinical data from its NKX101 NK cell therapy program. NKX101 is designed as an allogeneic, off-the-shelf immunotherapy targeting cancer cells through NKG2D ligands. This product utilizes engineered NK cells derived from healthy donors and aims to enhance the persistence of the immune response against tumors. The call demonstrates Nkarta's focus on keeping stakeholders informed about the progress of their clinical trials.
Read more →NKTXNkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
Nkarta, Inc. presented positive preliminary clinical data for NKX019 at the EHA 2023 Congress and 17-ICML. The Phase 1 trial showed a 70% complete response rate among patients with relapsed/refractory non-Hodgkin lymphoma, with no observed severe side effects. The results suggest that NKX019 might be a safe and effective outpatient therapy option for these patients. Future updates on the NKX019 program are anticipated later this year.
Read more →NKTXNkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
Nkarta, Inc. will present preliminary data from its Phase 1 dose escalation trial of NKX019 at two notable conferences in June 2023. The trial focuses on NKX019, an allogeneic CAR NK cell therapy aimed at treating relapsed/refractory B-cell malignancies. The data will be presented in a peer-reviewed format, providing insight into its efficacy and safety. Nkarta plans to provide updates later in 2023.
Read more →NKTXNkarta Reports First Quarter 2023 Financial Results and Corporate Highlights • Clinical updates on track for NKX101 in second quarter of 2023 at a company-hosted event and NKX019 in second half of 2023 • Ca
Nkarta, a clinical-stage biopharmaceutical company, reported its first quarter 2023 financial results, highlighting strong cash reserves of $332.1 million. The company is optimistic about its lead programs, NKX101 and NKX019, with anticipated clinical updates in 2023. Although the company reported a net loss of $30.8 million, it's expected to sustain operations into 2025. Furthermore, Nkarta's clinical updates are being planned for key scientific meetings, underscoring its ongoing commitment to advancing cell therapy options.
Read more →NKTXNkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
Nkarta, Inc. presented preclinical data at the 2023 AACR Annual Meeting demonstrating promising results for its NK cell therapies. Specifically, the company highlighted enhanced antibody-dependent cellular cytotoxicity (ADCC) using the ADAM17 gene knockout strategy and the potent effects of combining NKX101 with cetuximab against cancer cells. These findings suggest potential advancements in treating solid tumors and underscore the therapeutic benefits of combining engineered NK cells with monoclonal antibodies. The company is positioned for clinical applications of these therapies as it continues to develop its pipeline.
Read more →NKTXNkarta Announces Departure of Chief Financial & Business Officer • Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023
Nkarta, Inc. has announced the resignation of its Chief Financial and Business Officer, Nadir Mahmood, who will pursue a CEO position at another company. Despite this leadership transition, Nkarta is positioned to continue its clinical trials for NKX101 and NKX019, with the updates expected in 2023. The company has initiated a search for Mahmood's replacement while expressing gratitude for his contributions during his tenure. Nkarta's innovative therapies are aimed at addressing significant cancer treatment needs.
Read more →NKTXNkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights • Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023 • 2022 year-end cash and
Nkarta, Inc. has reported its fourth quarter and full year 2022 financial results, highlighting significant cash reserves and progress in its clinical pipeline. The company anticipates clinical updates for both NKX101 and NKX019 in 2023, with promising early results indicating substantial anti-tumor activity. However, Nkarta reported a net loss of $113.8 million for the year, which could pose challenges to its long-term financial health. The firm is committed to advancing its allogeneic NK cell therapy technology aimed at treating various cancers.
Read more →NKTX▼ -7.8%on this news
Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer
Nkarta, Inc. has promoted Dr. David R. Shook to Chief Medical Officer, effective January 9, 2023. Dr. Shook has played a pivotal role in developing Nkarta's clinical strategy for NK cell therapeutics since joining the company in 2020. He brings a wealth of experience from his previous roles at St. Jude Children's Research Hospital and has been integral in the advancement of clinical programs for Nkarta's novel cancer treatments. The company aims to transform patient care using its engineered NK cell therapies.
Read more →NKTX▼ -5.1%on this news
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma • 7 of 10 patients treated with NKX019 monotherapy at 1 billi
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma -7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response
Read more →NKTX▼ -5.1%on this news
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program Call scheduled for Monday
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 2, 2022 -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engi
Read more →NKTXNkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call on Monday, December 5, 2022 at 8:0
Read more →NKTX▼ -6.2%on this news
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights • NKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022 •
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights -NKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022 -NKX019 Phase 1 clinical trial recently opened dose expansion cohorts -Ne
Read more →NKTXNkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of Healthy Donors Induces Billion-Fold Expansion, Enabling Commercial-Scale Productio
Read more →NKTXNkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights • Positive preliminary data from NKX101 Phase 1 study in patients with relapsed / refractory AML and NKX019 Phase 1 study in patients w
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights -Positive preliminary data from NKX101 Phase 1 study in patients with relapsed / refractory AML and NKX019 Phase 1 study in patients with relapsed / refractory NHL validate the company's platform for e
Read more →NKTXNkarta Announces Key Senior Leadership Team Appointments
Ralph Brandenberger, PhD, promoted to Chief Technical Officer Yvonne Li, MBA, promoted to Chief Administrative Officer Evolution of Nkarta leadership team to support rapid development of allogeneic, off-the-shelf NK cell therapies SOUTH SAN FRANCISCO, Calif. , July 25, 2022 (G
Read more →NKTXNkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development SOUTH SAN FRANCISCO, Calif., May 16, 2022 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announ
Read more →NKTXNkarta Reports First Quarter 2022 Financial Results and Corporate Highlights • Positive preliminary data reported from NKX101 Phase 1 study in patients with relapsed / refractory AML; 3 of 5 patients treated with
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights -Positive preliminary data reported from NKX101 Phase 1 study in patients with relapsed / refractory AML; 3 of 5 patients treated with a 3-dose regimen of 1B or 1.5B CAR NK cells per dose achieved compl
Read more →NKTXNkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced the closing of its previously announced underwritten public offering of 13
Read more →NKTX▼ -10.3%on this newsshared move
Nkarta Announces Pricing of Upsized Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its
Read more →NKTX▲ +140.9%on this newsshared move
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs NKX101 3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell NKX101 3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5B CAR NK cells per dose achieved complete response with full hemato
Read more →NKTX▲ +140.9%on this newsshared move
Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates Call scheduled for Monday
Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates Call scheduled for Monday, April 25, 2022 8:00 a.m. ET Clinical trial investigators to participate SOUTH SAN FRANCISCO, Calif., Apr. 22, 2022 -- Nkarta, Inc. (Nasdaq
Read more →NKTX▲ +140.9%on this newsshared move
Nkarta Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced that it has commenced a proposed underwritten public offering to issue and
Read more →NKTXNkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates
Call scheduled for Monday, April 25, 2022 8:00 a.m. ET Clinical trial investigators to participate SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies t
Read more →NKTX▼ -6.7%on this news· ran to -24% by day 3
Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022
SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its na
Read more →NKTX▲ +6.8%on this news
Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors Appointment brings extensive operational expertise in supply chain and novel commercial-scale manufacturing systems SOUTH SAN FRA
Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors Appointment brings extensive operational expertise in supply chain and novel commercial-scale manufacturing systems SOUTH SAN FRANCISCO, Calif. Mar. 29, 2022 Nkarta, Inc. (Nasdaq: NKTX),
Read more →NKTX▲ +10.7%on this news
Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights • On track to announce initial Phase 1 clinical trial data from two co-lead programs in 2022 – 1H 2022 - NKX101, a
Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights -On track to announce initial Phase 1 clinical trial data from two co-lead programs in 2022 1H 2022 - NKX101, a CAR NK cell therapy candidate engineered with NKG2D receptor, in relapsed/
Read more →NKTXNkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will present four posters at the upcoming American Associatio
Read more →NKTXNkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has gr
Read more →NKTX▼ -6.6%on this newsshared move
Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today presented a trial in progress poster on NKX019 for the treatment of relapsed and
Read more →NKTX▲ +6.4%on this news
Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its nat
Read more →NKTXNkarta Reports Third Quarter 2021 Financial Results and Business Update Initial data expected in 1H 2022 from Phase 1 clinical trial of NKX101 in AML and MDS Successful dosing of NKX019 in patients with B cell malignanci
Nkarta Reports Third Quarter 2021 Financial Results and Business Update SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial resul
Read more →NKTXNkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs First patients dosed in Phase 1 clinical trial evaluating NKX019 in CD19+ advanced B cell malignancies Initial data from the NKX019 clinical tri
Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs SOUTH SAN FRANCISCO, Calif., Oct. 7, 2021 -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced NKX019 and
Read more →NKTXNkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting
Data support potential clinical applications of CRISPR/Cas9 genome engineering, CD70 chimeric antigen receptor (CAR) targeting, and donor selection algorithms in next generation NK cell development programs Update also highlights novel methods for scaling the expansion of engine
Read more →NKTXNkarta Reports Second Quarter 2021 Financial Results and Business Progress Initial data from NKX101 clinical trial expected by end of 2021 NKX019 patient dosing expected to start in 2H 2021 Collaboration with CRISPR Ther
Nkarta Reports Second Quarter 2021 Financial Results and Business Progress SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial re
Read more →NKTXNkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters 88,000 square foot facility in South San Francisco will support scaled manufacturing of Nkarta's engineered NK cell therapy ca
Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters SOUTH SAN FRANCISCO, Calif., July 14, 2021 -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today an
Read more →NKTXNkarta to Present at Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference: Raymond James
Read more →NKTXNkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term
SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that Chief Executive Officer Paul Hastings has been elected as the Cha
Read more →NKTXNkarta Announces June 2021 Investor Conference Schedule
SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference: Jefferies Virt
Read more →NKTXNkarta Reports First Quarter 2021 Financial Results and Business Progress NKX019 IND received FDA clearance; NKX019 patient dosing expected to start in 2H 2021 Protocol amendment to ongoing NKX101 clinical trial adds a s
Nkarta Reports First Quarter 2021 Financial Results and Business Progress SOUTH SAN FRANCISCO, Calif., May 13, 2021 -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial resu
Read more →NKTXCRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer -Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer -Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilitie
Read more →NKTXNkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies NKX019 to be Nkarta's second CAR NK pipeline program to enter clinical trial
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies SOUTH SAN FRANCISCO, Calif., April 28, 2021 - Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) c
Read more →NKTXNkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress Continued progress in dosing of patients in clinical trial of NKX101, investigational CAR NK cell therapy engineered wit
Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress SOUTH SAN FRANCISCO, Calif., March 25, 2021 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to
Read more →NKTXNkarta Announces February and March 2021 Investor Conference Schedule
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conference
Read more →NKTXNkarta Reports Third Quarter 2020 Financial Results • First patient dosed in clinical trial of NKX101, investigational NK cell therapy engineered with NKG2D-targeted CAR, in acute myeloid leukemia and myelodysplas
Nkarta Reports Third Quarter 2020 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results fo
Read more →NKTXNkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the first patient has been treated in the first-in
Read more →NKTXNkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced a preclinical update on NKX019, its investigational all
Read more →NKTXNkarta Announces November & December 2020 Investor Conference Schedule
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conference
Read more →NKTXNkarta Announces Leadership Changes
Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business Officer Alicia J. Hager, J.D., Ph.D. to Join as Chief Legal Officer SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company
Read more →NKTXNkarta Announces Leadership Changes Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business Officer Alicia J. Hager, J.D., Ph.D. to Join as Chief Legal Officer
Nkarta Announces Leadership Changes Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business Officer Alicia J. Hager, J.D., Ph.D. to Join as Chief Legal Officer SOUTH SAN FRANCISCO, Calif., October 5, 2020 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage bio
Read more →NKTXNkarta Announces October 2020 Investor Conference Schedule
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will participate at the following virtual inve
Read more →NKTXNkarta Announces September 2020 Virtual Investor Conference Schedule
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will participate at the following virtual inve
Read more →NKTXNkarta Reports Second Quarter 2020 Financial Results • Co-Lead programs on track: NKX101 expected to begin Phase 1 dosing in 4Q 2020 and IND for NKX019 expected to be filed in 1Q 2021 • Completed constructi
Nkarta Reports Second Quarter 2020 Financial Results SOUTH SAN FRANCISCO, Calif., August 20, 2020 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results
Read more →NKTXNkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters Option to Purchase Additional Shares Underwriters Full Exercise of Option Brings Gross Proceeds to $289.8 Million South San
Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters Option to Purchase Additional Shares Underwriters Full Exercise of Option Brings Gross Proceeds to $289.8 Million South San Francisco, July 14, 2020 Nkarta, Inc. (Nasdaq: NKTX), a
Read more →NKTXNkarta Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the pricing of its initial public offering of 14,000,000 shares
Read more →NKTXNkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II
Gene editing of engineered natural killer cells contributed to enhanced cell persistence and tumor killing Combination of engineered natural killer cells and engineered T cells demonstrated potential to achieve improved tumor control, optimized cell proliferation and moderate le
Read more →NKTXNkarta Therapeutics Appoints Two New Independent Directors
SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nkarta), a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, announced today the appointments of Laura K. Shawver, Ph.D. and Leone Patter
Read more →NKTXNkarta Therapeutics to Present at the J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, announced today that the company’s chief executive officer, Paul Hastings, will
Read more →NKTXNkarta Therapeutics Expands Senior Management Team with Key Hires in Finance and Clinical Development
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight cancer, today announced the addition of two key members to its senior management team.
Read more →NKTXNkarta Therapeutics Presents Preclinical Data for CD19 CAR NK Program
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight cancer, today announced preclinical data were presented in a poster session at the Amer
Read more →NKTXNkarta Therapeutics Named as a “Fierce 15” Biotechnology Company of 2019
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight cancer, today announced that FierceBiotech has named it as a “Fierce 15” biotechnology
Read more →NKTXNkarta Therapeutics Promotes Nadir Mahmood, Ph.D., to Chief Business Officer
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight cancer, today announced the promotion of Nadir Mahmood, Ph.D., to the newly-created po
Read more →NKTXNkarta Therapeutics Appoints Vice President of Regulatory Affairs
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight cancer, today announced the appointment of Lisa Arjes as vice president of regulatory
Read more →NKTXNkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trials
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight cancer, today announced that it has closed an oversubscribed $114 million Series B fin
Read more →NKTXNkarta Therapeutics Presents Data at AACR Demonstrating Proprietary NK Cell Engineering and Expansion Technology Enhances Potency and Cytotoxicity of NK Cells
SOUTH SAN FRANCISCO, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing engineered Natural Killer (NK) cell therapies to fight cancer, today announced preclinical data were presented in a poster session at the American
Read more →NKTXNkarta Therapeutics Announces Appointment of Matthew Plunkett, Ph.D., as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing engineered Natural Killer (NK) immune cells to fight cancer, today announced that Matthew Plunkett, Ph.D., has joined as senior vice president and
Read more →NKTXNkarta Therapeutics Appoints Kanya Rajangam, M.D., Ph.D, as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced that it has named Kanya Rajangam, M.D., Ph.D., as senior vice president and chief
Read more →NKTXNkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity in Preclinical Tumor Model
NK cell potency and persistence significantly improved using cell engineering technology 60% increase in cytotoxicity observed with Nkarta NK cells relative to control NK cells Single in vivo administration of engineered NK Cells led to durable tumor suppression in a xenograft
Read more →NKTXNkarta Therapeutics Expands Management Team and Establishes New Corporate Headquarters
SOUTH SAN FRANCISCO, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced two new additions to its management team with the appointments of Nadir Mahmood,
Read more →NKTXNkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology From National University of Singapore and St. Jude Children’s Research Hospital
SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced that it has entered into a worldwide exclusive license agreement for proprietary
Read more →NKTXNkarta Therapeutics Appoints Veteran Executive Paul Hastings as CEO to Lead Next Phase of Growth
SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing natural killer (NK) immune cells to fight cancer, announced that it has named industry biotech veteran, Paul Hastings, as chief executive officer.
Read more →Competitive Position
How NKTX ranks across every disease it competes inCompetitive Position is a premium feature
See how NKTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial